神経障害性疼痛治療薬の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Neuropathy Pain Treatment Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of neuropathic pain

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by indication
• Diabetic neuropathy
• Chemotherapy-induced neuropathy pain
• Postherpetic neuralgia
• Others

PART 09: Market segmentation by drug class
• Calcium channel alpha 2-delta ligands
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)
• TCAs
• Opioid analgesics
• Others

PART 10: Geographical segmentation
• Neuropathy pain treatment market in Americas
• Neuropathy pain treatment market in EMEA
• Neuropathy pain treatment market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 13: Market trends
• Development of topical patches for the treatment of neuropathic pain likely to change market dynamics
• Growing focus on emerging economies
• Increasing mergers and acquisitions would lead to further consolidation

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• Depomed
• Eli Lilly
• Endo International
• Pfizer
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Global neuropathy pain treatment market snapshot
Exhibit 02: Global neuropathic pain treatment market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global neuropathy pain treatment market
Exhibit 04: Five forces analysis
Exhibit 05: Key pipeline candidates by indication
Exhibit 06: Pipeline analysis
Exhibit 07: Global neuropathy pain treatment market segmentation by indication 2016
Exhibit 08: Global diabetic neuropathy market 2016-2021 ($ millions)
Exhibit 09: Global chemotherapy-induced neuropathic pain drugs market 2016-2021 ($ millions)
Exhibit 10: Global postherpetic neuralgia drugs market 2016-2021 ($ millions)
Exhibit 11: Global other neuropathy pain drugs market 2016-2021 ($ millions)
Exhibit 12: Neuropathy pain market by drug class 2016
Exhibit 13: Segmentation of global neuropathy pain treatment market based on geography 2016 and 2021
Exhibit 14: Neuropathy pain treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Neuropathic pain treatment market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: Neuropathy pain treatment market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Neuropathic pain treatment market in APAC 2016-2021 ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Impact of challenges
Exhibit 23: Competitive structure analysis of global neuropathic pain treatment market 2016
Exhibit 24: Competitive analysis of global neuropathic pain treatment market
Exhibit 25: Strategic success factors of companies in global neuropathic pain treatment market
Exhibit 26: Depomed: Key highlights
Exhibit 27: Depomed: Strength assessment
Exhibit 28: Depomed: Strategy assessment
Exhibit 29: Depomed: Opportunity assessment
Exhibit 30: Eli Lilly: Key highlights
Exhibit 31: Eli Lilly: Strength assessment
Exhibit 32: Eli Lilly: Strategy assessment
Exhibit 33: Eli Lilly: Opportunity assessment
Exhibit 34: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
Exhibit 35: Endo International: Key highlights
Exhibit 36: Endo International: Strength assessment
Exhibit 37: Endo International: Strategy assessment
Exhibit 38: Endo International: Opportunity assessment
Exhibit 39: Endo International: YoY and growth rate of LIDODERM (branded) 2013-2015 ($ millions)
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Pfizer: YoY and growth rate of LYRICA 2013-2015 ($ millions)
Exhibit 45: Pfizer: YoY and growth rate of NEURONTIN 2013-2015 ($ millions)


【レポート販売概要】

■ タイトル:神経障害性疼痛治療薬の世界市場2017-2021
■ 英文:Global Neuropathy Pain Treatment Market 2017-2021
■ 発行日:2017年3月7日
■ 調査会社:Technavio
■ 商品コード:IRTNTR12164
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。